PreveCeutical Announces Successful Completion from its Design, Synthesis and Preliminary Evaluation of Novel Designed Peptides Derived from Caribbean Blue Scorpion Venom in a Cell-Based Brain Cancer Model
cannabis investing PreveCeutical Receives $616,802 AUD Research and Development Tax Incentive Cash Refund
cannabis investing PreveCeutical Announces the Successful Engineering & Cell-Based Efficacy Screening of its Smart-siRNA Constructs for its Dual Gene Therapy Research Program
cannabis investing PreveCeutical Reaches Milestone in Research Program for Development of Non-Addictive Analgesics
cannabis investing PreveCeutical Grants Asterion Option to Purchase up to a 51% Interest in Sol-Gel Intellectual Property
cannabis investing PreveCeutical Announces Default Judgment Against Essos Corporate Services Inc. and Detona Capital Corp.
cannabis investing PreveCeutical Provides Update on Research Program for Development of Non-Addictive Analgesics
